Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

BACKGROUND: Elevated proinflammatory cytokines are associated with greater COVID-19 severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical (requiring greater...

Descripción completa

Detalles Bibliográficos
Autores principales: Lescure, François-Xavier, Honda, Hitoshi, Fowler, Robert A, Lazar, Jennifer Sloane, Shi, Genming, Wung, Peter, Patel, Naimish, Hagino, Owen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078879/
https://www.ncbi.nlm.nih.gov/pubmed/33676590
http://dx.doi.org/10.1016/S2213-2600(21)00099-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078879/
https://www.ncbi.nlm.nih.gov/pubmed/33676590
http://dx.doi.org/10.1016/S2213-2600(21)00099-0

Ejemplares similares